IMRX — Immuneering Corp
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1790340 ·
Last close
$3.74
Market Cap
$241.97M
52W High
$8.48
52W Low
$3.60
ADV30
736,018
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -18,999,964 | -17,270,427 | 202,055,327 | 41,324,682 | 11,320,301 |
| Mar 2026 | 0 | — | -15,334,539 | -13,460,895 | 214,809,790 | 47,321,566 | 8,291,619 |
| Dec 2025 | 0 | — | -13,751,943 | -11,580,010 | 231,985,010 | 128,645,025 | 13,501,042 |
| Sep 2025 | 0 | — | -15,380,300 | -14,964,875 | 241,056,266 | 227,563,077 | 13,079,834 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-56,752,670
Investing CF
$-141,318,060
Financing CF
$213,039,914
CapEx
$-238,462
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.04
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-311,051,406
Inventory
—
Receivables
—
ST Investments
$108,575,637
EBIT TTM
$-63,466,746
Pretax Income TTM
$-57,274,086
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -59,375,728 | -56,024,898 | 231,985,010 | 13,501,042 | 218,483,968 | -45,344,595 |
| Dec 2024 | 0 | -64,071,655 | -61,036,608 | 52,714,413 | 11,328,187 | 41,386,226 | -54,999,571 |
| Dec 2023 | 0 | -58,413,285 | -53,471,622 | 102,584,538 | 12,008,355 | 90,576,183 | -48,968,634 |
| Dec 2022 | 316,952 | -51,745,339 | -50,513,568 | 122,367,283 | 12,517,028 | 109,850,255 | -44,101,265 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$3,961,290
NetIncome TTM
$-54,439,661
OpCashFlow TTM
—
Assets (Latest)
$214,809,790
Forward EPS
$-1.26
Max Pain — expiry 2026-10-16
max pain strike: $5.00 · spot: $3.74 · call oi: 1,287 · put oi: 100
Expected Move to 2026-10-16:
±$1.92
(51.34%) —
implied range
$1.82 –
$5.66
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| QTTB | Q32 Bio Inc. | $240.83M | $8.09 | — |
| LFCR | LIFECORE BIOMEDICAL, INC. \DE\ | $243.40M | $6.43 | — |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $237.63M | $2.51 | — |
| VCRE | Vicore Pharma Holding AB | $248.41M | $8.82 | — |
| SIGA | SIGA TECHNOLOGIES INC | $235.67M | $3.28 | — |
News headlines (Yahoo Finance, 1h cache)
Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
2026-10-02 13:00 · Yahoo
Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer
2026-09-28 11:30 · Yahoo
Immuneering to Present at the ESMO Congress 2026
2026-09-24 11:30 · Yahoo
Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival
2026-09-10 11:30 · Yahoo
Immuneering to Participate in Upcoming Investor Conferences
2026-09-03 20:05 · Yahoo
Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
2026-08-26 21:16 · Yahoo
Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-08-05 11:30 · Yahoo
Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition
2026-07-21 20:05 · Yahoo
Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know
2026-07-15 16:00 · Yahoo
Immuneering Appoints Andrew Gengos as Chief Financial Officer
2026-06-15 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.